|Bid||13.99 x 1100|
|Ask||14.12 x 800|
|Day's Range||12.82 - 14.11|
|52 Week Range||9.59 - 29.55|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||32.90|
During the first half of the fourth quarter the Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by about 4 percentage points as investors worried over the possible ramifications of rising interest rates. The hedge funds and institutional investors we track typically invest more in smaller-cap stocks than an average investor (i.e. […]
Phase 2/3 Expansion Study to Include No-Sham Control Arm in Alignment with FDA Draft Guidance on Development of Gene Therapy Products for Retinal Disorders Preliminary Efficacy.
WALTHAM, Mass. and LONDON, Nov. 08, 2018 -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal.
NEW YORK, Oct. 23, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
The bullish case for Applied Genetic Technologies Corp (NASDAQ: AGTC ), a nano-cap biotech conducting human clinical trials of adeno-associated virus-based gene therapies, can be made on the basis of an ...
Innovation has always been the mantra when it comes to biotech stocks. Gene therapy is quickly becoming the technique du jour for curing orphan and rare diseases. In a nutshell, gene therapy is fixing those problems by either adding new genes to fight the faulty ones, replacing/editing missing/broken prices or actually “turning off” the genes causing problems.
Nightstar retains close ties with the University of Oxford, which provides academic expertise as well as strong results from prior studies and the preclinical development of two new programs, Zhong said in the initiation note.
Nightstar Therapeutics (NITE) was a big mover last session, as the company saw its shares rise more than 6% on the day.
While steady growth is appreciated by some investors, that’s not that great overall and doesn’t necessarily support its constant valuation premium. To that end, Johnson & Johnson needs to find some serious growth to keep investors coming back to its shares. Vision care is quickly becoming a major growth engine for JNJ.